Swedish Orphan Biovitrum AB (SOBI) reports it has dosed first patient in its Phase 1/2 clinical trial evaluating SOB1003 to treat Sanfilippo syndrome type A.  Two key research sites include Children’s Hospital and Research Center, Oakland California and the University...